EyePoint EYPT 深 沪
已收盘 08-07 16:00:00 美东时间
13.89
+1.060
+8.26%
华盛通- 最 高14.08
- 今 开13.04
- 成交量 165.57万股
- 最 低 13.0286
- 昨 收 12.83
- 总市值 11.65亿
- 52周最高 19.11
- 市盈率 静 --
- 换手率 1.97%
- 52周最低 9.65
- 委 比 -52.38%
- 总股本 8384.13万
- 历史最高 39.40
- 量 比 0.77
- 振 幅 8.19%
- 历史最低 2.19
- 每 手 1
- 风险率 1.86%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 花旗、富国下调闪迪目标价，低至1400美元；百济神州、多邻国、DoorDash、Shopify等获多家机构上调评级
今日重点评级关注：康托·菲茨杰拉德：维持EyePoint"超配"评级，目标价从47美元升至55美元；伯恩斯坦：维持Figure Technology"跑赢大市"评级，目标价从67美元升至70美元
08-07 13:41
HC Wainwright & Co. Maintains Buy on EyePoint, Lowers Price Target to $27
HC Wainwright & Co. analyst Yi Chen maintains EyePoint (NASDAQ:EYPT) with a Buy and lowers the price target from $30 to $27.
08-06 18:54
EyePoint rises after enrollment update on Duravyu late-stage trials
Shares of EyePoint (EYPT) gained on Thursday after the company said that two late-stage trials for its lead asset, Duravyu, completed enrollments ahead of schedule, validating its confidence in the pr...
07-31 01:52
EyePoint completes Phase 3 DURAVYU enrollment for DME
EyePoint Pharmaceuticals ( ($EYPT) ) has provided an announcement. On July 30, ...
07-30 19:29
EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU™ for Treatment of Diabetic Macular Edema (DME)
EyePoint, Inc. announced the completion of enrollment for its COMO and CAPRI Phase 3 clinical trials for DURAVYU™, a treatment for diabetic macular edema (DME). Over 480 participants were enrolled in five months, ahead of schedule. Topline data from both trials is expected in the fourth quarter of 2027. DURAVYU™ aims to provide a more durable and differentiated treatment option with a sustained drug delivery system targeting both VEGF and inflamm...
07-30 11:00
EyePoint Pharmaceuticals Settles DEXYCU Case, Enhances Compliance Oversight
An update from EyePoint Pharmaceuticals ( ($EYPT) ) is now available. On July 1...
07-18 05:34
EyePoint Pharmaceuticals To Pay $4.6M to Resolve False Claims Act Allegations
https://www.justice.gov/opa/pr/eyepoint-pharmaceuticals-pay-46-million-resolve-false-claims-act-allegations
07-17 22:22
美股大行评级 | 阿斯麦、贝莱德、纽约梅隆银行、信达思、JB亨特运输服务、美国制商银行、PNC金融服务集团等获多家大行集体上调目标价
今日重点评级关注：瑞杰金融：维持Electrovaya"强力买入"评级，目标价从14美元升至22美元；BTIG：维持vTv Therapeutics"买入"评级，目标价从49美元升至57美元
07-17 11:35
Stifel Initiates Coverage On EyePoint with Buy Rating, Announces Price Target of $40
Stifel analyst Annabel Samimy initiates coverage on EyePoint (NASDAQ:EYPT) with a Buy rating and announces Price Target of $40.
07-16 17:48
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint, Inc. granted non-statutory stock options to two new employees, totaling 63,500 shares, as inducement awards under NASDAQ Listing Rule 5635(c)(4). The options, with an exercise price of $13.85 per share, vest over four years and have a ten-year term. EyePoint, a biopharmaceutical company, is developing DURAVYU™, an investigational treatment for retinal diseases, currently in Phase 3 trials for wet AMD and DME. The company is based in Wat...
07-16 11:00
